• The Lead Episode 30: A Discussion of Return-to-Play for Elite Athletes with Genetic Heart Diseases
• Predisposing to Sudden Cardiac Death
• Arrhythmias and Athletes (HROD2023)
• Sudden Cardiac Arrest on the Athletic Field (HROD2023)
• EP on EP Episode 41 – ICDs in Athletes
• EP on EP Episode 91: Return to Sports (Part 1)
• EP on EP Episode 93: Return to Sports (Part 2)
• HR2022 – Course Clinical EP – Controversies in Arrhythmia Management in Athletes

• Identify best treatment strategies for the treatment of AFib in athletes
• Outline how to risk stratify athletes with frequent PVCs.
• Review the difficult decision of return to play for survivors of cardiac arrest.

Faculty Disclosure(s):

M.J. Ackerman: Honoraria/Speaking/Consulting Fee - Boston Scientific; Daiichi Sankyo; UpToDate; Medtronic; ARMGO Pharma; LQT Therapeutics; Abbott; Bristol-Myers Squibb. Intellectual Property Rights - AliveCor; Anumana; Pfizer, Inc.. Research (Contracted Grants for PIs and Named Investigators only) - LQT Therapeutics.

Bryan Baranowski: Nothing Relevant to Disclose.

Neal Bhatia: Nothing Relevant to Disclose

T. Bunch: Research (Contracted Grants for PIs and Named Investigators only) - Altathera; Boehringer Ingelheim; Abbott. Training for new ablation balloon - Biosense Webster, Inc.. Honoraria/Speaking/Consulting Fee - Pfizer, Inc..

E.H. Chung: Nothing relevant to disclose.

James Daubert:  Research (Contracted Grants for PIs and Named Investigators only): Boston Scientific, Medtronic, Honoraria/Speaking/Consulting: VytronUS, Inc., LivaNova, Boston Scientific, Medtronic, Biosense Webster, Inc., Syneos Health, Acutus Medical Inc, Farapulse, Biotronik, Philips, Affera, Inc.

S.P. Etheridge: Nothing relevant to disclose.

Ann Garlitski: Cohere Health (Honoraria/Speaking/Consulting Fee), Boston Scientific (Salary from Employment)

T.V. Glotzer: Honoraria/Speaking/Consulting Fee - Abbott; Medtronic,Inc..

S. Iwai: No relevant financial relationships with ineligible companies to disclose.

J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stocks (Privately Held): Atlas 5D

Elizabeth Kaufman: Nothing Relevant to Disclose

R. Lampert: Honoraria/Speaking/Consulting Fee: Medtronic; Research (Contracted Grants for PIs Named Investigators Only): MediLynx, Medtronic, Boston Scientific, Medtronic Inc..

Christopher Madias: Nothing Relevant to Disclose

J.M. Mandrola: Nothing relevant to disclose.

M. Maron: Research (Contracted Grants for PIs and Named Investigators only) - iRhythm Technologies; Celltrion; Takeda; Imbria. chair, Steering Committte - Cytokinetics.

Eric N. Prystowski, MD,FHRS: Honoraria/Speaking/Consulting: Medtronic, Philips

Marwan Refaat: Nothing Relevant to Disclose

Comilla Sasson: Nothing Relevant to Disclose

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Colbert: No relevant financial relationships with ineligible companies to disclose.
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Kane: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.

Disclosure Policy

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.

Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.

ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

• Advertising, marketing, or communication firms whose clients are ineligible companies
• Bio-medical startups that have begun a governmental regulatory approval process
• Compounding pharmacies that manufacture proprietary compounds
• Device manufacturers or distributors
• Diagnostic labs that sell proprietary products
• Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
• Manufacturers of health-related wearable products
• Pharmaceutical companies or distributors
• Pharmacy benefit managers
• Reagent manufacturers or sellers

All relevant financial relationships have been mitigated.